

DAFTAR PUSTAKA

- Ari, H., Oztas Cosar, S., Ari, S., Doganay, K., Aydin, C., Emlek, N et al., (2016). Incidence and risk factors of contrast-induced nephropathy after diagnostic or interventional coronary angiography. *The European Research Journal*, 0(0). <https://doi.org/10.18621/eurj.2016.5000200322>
- Bhatt, D. L., Lopes, R. D., & Harrington, R. A. (2022). Diagnosis and Treatment of Acute Coronary Syndromes: A Review. *JAMA*, 327(7), 662. <https://doi.org/10.1001/jama.2022.0358>
- Borer, J. S. (2007). Angiotensin-converting enzyme inhibition: A landmark advance in treatment for cardiovascular diseases. *European Heart Journal Supplements*, 9(suppl_E), E2–E9. <https://doi.org/10.1093/eurheartj/sum037>
- Bueno, H. (2018). Epidemiology of acute coronary syndromes. In S. James (Ed.), *ESC CardioMed* (pp. 1213–1218). Oxford University Press. <https://doi.org/10.1093/med/9780198784906.003.0305>
- Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A et al., (2023). 2023 ESC Guidelines for the management of acute coronary syndromes. *European Heart Journal*, 44(38), 3720–3826. <https://doi.org/10.1093/eurheartj/ehad191>
- Chapman, A. R., Stewart, S., & Mills, N. L. (2019). Contemporary point of care cardiac troponin testing in suspected acute coronary syndrome. *Heart*, 105(10), 740–741. <https://doi.org/10.1136/heartjnl-2018-314306>
- Chew, D. P., Scott, I. A., Cullen, L., French, J. K., Briffa, T. G., Tideman, P. A et al., (2016). National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016. *Heart, Lung and Circulation*, 25(9), 895–951. <https://doi.org/10.1016/j.hlc.2016.06.789>
- Cho, E., & Ko, G.-J. (2022). The Pathophysiology and the Management of Radiocontrast-Induced Nephropathy. *Diagnostics*, 12(1), 180. <https://doi.org/10.3390/diagnostics12010180>
- Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L et al., (2021). 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *European Heart Journal*, 42(14), 1289–1367. <https://doi.org/10.1093/eurheartj/ehaa575>
- Crea, F., Koledgie, F., Finn, A., & Virmani, R. (2022). Mechanisms of acute coronary syndromes related to atherosclerosis. *UpToDate*. <https://www.uptodate.com/contents/mechanisms-of-acute-coronary-syndromes-related-to-atherosclerosis>
- Eknoyan, G., & Lameire, N. (2012). Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for

- Acute Kidney Injury. *Kidney International Supplements*, 2(1), 19–36. <https://doi.org/10.1038/kisup.2011.32>
- Evans, M., Carrero, J.-J., Szummer, K., Åkerblom, A., Edfors, R., Spaak, J et., (2016). Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction. *Journal of the American College of Cardiology*, 67(14), 1687–1697. <https://doi.org/10.1016/j.jacc.2016.01.050>
- Ezzati, M., Lopez, A. D., Rodgers, A., Vander Hoorn, S., & Murray, C. J. (2002). Selected major risk factors and global and regional burden of disease. *The Lancet*, 360(9343), 1347–1360. [https://doi.org/10.1016/S0140-6736\(02\)11403-6](https://doi.org/10.1016/S0140-6736(02)11403-6)
- Ghazi, L., & Drawz, P. (2017). Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy. *F1000Research*, 6, 297. <https://doi.org/10.12688/f1000research.9692.1>
- Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C. (2004). Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. *New England Journal of Medicine*, 351(13), 1296–1305. <https://doi.org/10.1056/NEJMoa041031>
- González-Cambeiro, M. C., López-López, A., Abu-Assi, E., Raposeiras-Roubín, S., Peña-Gil, C., García-Acuña, J et al., (2016). Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction. *Revista Portuguesa de Cardiologia*, 35(12), 645–653. <https://doi.org/10.1016/j.repc.2016.07.003>
- Gupta, R. K., Kapoor, A., Tewari, S., Sinha, N., & Sharma, R. K. (1999). Captopril for prevention of contrast-induced nephropathy in diabetic patients: A randomised study. *Indian Heart Journal*, 51(5), 521–526.
- Holmström, L., Juntunen, S., Vähätalo, J., Pakanen, L., Kaikkonen, K., Haukilahti, A et al., (2022). Plaque histology and myocardial disease in sudden coronary death: The Fingerture study. *European Heart Journal*, 43(47), 4923–4930. <https://doi.org/10.1093/eurheartj/ehac533>
- Hsu, T.-W., Liu, J.-S., Hung, S.-C., Kuo, K.-L., Chang, Y.-K., Chen, Y.-C et al., (2014). Renoprotective Effect of Renin-Angiotensin-Aldosterone System Blockade in Patients With Predialysis Advanced Chronic Kidney Disease, Hypertension, and Anemia. *JAMA Internal Medicine*, 174(3), 347. <https://doi.org/10.1001/jamainternmed.2013.12700>
- Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H et al., (2018). 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *European Heart Journal*, 39(2), 119–177. <https://doi.org/10.1093/eurheartj/ehx393>
- Izuhara, Y., Nangaku, M., Inagi, R., Tominaga, N., Aizawa, T., Kurokawa, K et al., (2005). Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood

- Pressure Lowering. *Journal of the American Society of Nephrology*, 16(12), 3631–3641. <https://doi.org/10.1681/ASN.2005050522>
- James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J et al., (2014). 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). *JAMA*, 311(5), 507. <https://doi.org/10.1001/jama.2013.284427>
- Jo, S.-H., Lee, J. M., Park, J., & Kim, H.-S. (2015). The Impact of Renin-Angiotensin-Aldosterone System Blockade on Contrast-Induced Nephropathy: A Meta-Analysis of 12 Studies with 4,493 Patients. *Cardiology*, 130(1), 4–14. <https://doi.org/10.1159/000366473>
- Kerneis, M., Nafee, T., Yee, M. K., Kazmi, H. A., Datta, S., Zeitouni, M et al., (2019). Most Promising Therapies in Interventional Cardiology. *Current Cardiology Reports*, 21(4), 26. <https://doi.org/10.1007/s11886-019-1108-x>
- Khan, S. Q., & Ludman, P. F. (2022). Percutaneous coronary intervention. *Medicine*, 50(7), 437–444. <https://doi.org/10.1016/j.mpmed.2022.04.008>
- Khera, S., Kolte, D., & Bhatt, D. L. (2016). Percutaneous Coronary Intervention. In *Translational Research in Coronary Artery Disease* (pp. 179–194). Elsevier. <https://doi.org/10.1016/B978-0-12-802385-3.00016-4>
- Kim, Y. H., Her, A.-Y., Jeong, M. H., Kim, B.-K., Lee, S.-Y., Hong, S.-J et al., (2019). Impact of renin-angiotensin system inhibitors on long-term clinical outcomes in patients with acute myocardial infarction treated with successful percutaneous coronary intervention with drug-eluting stents: Comparison between STEMI and NSTEMI. *Atherosclerosis*, 280, 166–173. <https://doi.org/10.1016/j.atherosclerosis.2018.11.030>
- Ksiazek, S. H., Hu, L., Andò, S., Pirklbauer, M., Säemann, M. D., Ruotolo, C et al., (2024). Renin–Angiotensin–Aldosterone System: From History to Practice of a Secular Topic. *International Journal of Molecular Sciences*, 25(7), 4035. <https://doi.org/10.3390/ijms25074035>
- Lawton, J. S., Tamis-Holland, J. E., Bangalore, S., Bates, E. R., Beckie, T. M., Bischoff, J. M et al.,(2022). 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. *Journal of the American College of Cardiology*, 79(2), e21–e129. <https://doi.org/10.1016/j.jacc.2021.09.006>
- Li, X., Li, T., Fu, N., Hu, Y., & Cong, H. (2012). Is angiotensin-converting enzyme inhibitor appropriate for contrast-induced nephropathy? A meta-analysis about this field. *International Journal of Cardiology*, 155(3), 486–488. <https://doi.org/10.1016/j.ijcard.2011.12.067>
- Lukito, A. A., Harmeiwaty, E., & Hustrini, N. M. (2019). *Konsensus Penatalaksanaan Hipertensi 2019*. Indonesian Society of Hypertension.
- Ma, M., Wan, X., Gao, M., Pan, B., Chen, D., Sun, Q et al.,(2020). Renin-angiotensin-aldosterone system blockade is associated with higher risk of contrast-induced

- acute kidney injury in patients with diabetes. *Aging*, 12(7), 5858–5877. <https://doi.org/10.18632/aging.102982>
- Makris, K., & Spanou, L. (2016). Acute Kidney Injury: Definition, Pathophysiology and Clinical Phenotypes. *The Clinical Biochemist. Reviews*, 37(2), 85–98.
- Marenzi, G., Cosentino, N., & Bartorelli, A. L. (2015). Acute kidney injury in patients with acute coronary syndromes. *Heart*, 101(22), 1778–1785. <https://doi.org/10.1136/heartjnl-2015-307773>
- McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M et al., (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *European Heart Journal*, 42(36), 3599–3726. <https://doi.org/10.1093/eurheartj/ehab368>
- Mohammed, NazarM. A., Rafie, I., Mahfouz, A., Achkar, K., & Hajar, R. (2013). Contrast-induced nephropathy. *Heart Views*, 14(3), 106. <https://doi.org/10.4103/1995-705X.125926>
- O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., De Lemos, J. A et al., (2013). 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*, 127(4). <https://doi.org/10.1161/CIR.0b013e3182742cf6>
- Ortega-Hernández, J., Springall, R., Sánchez-Muñoz, F., Arana-Martinez, J.-C., González-Pacheco, H., & Bojalil, R. (2017). Acute coronary syndrome and acute kidney injury: Role of inflammation in worsening renal function. *BMC Cardiovascular Disorders*, 17(1), 202. <https://doi.org/10.1186/s12872-017-0640-0>
- Peng, F., Su, J., Lin, J., & Niu, W. (2015). Impact of Renin-Angiotensin-Aldosterone System-blocking Agents on the Risk of Contrast-induced Acute Kidney Injury: A Prospective Study and Meta-analysis. *Journal of Cardiovascular Pharmacology*, 65(3), 262–268. <https://doi.org/10.1097/FJC.0000000000000189>
- PERKI. (2016). *Panduan Praktik Klinis (Ppk) Dan Clinical Pathway (Cp) Penyakit Jantung Dan Pembuluh Darah (Pertama)*. 2016.
- Prosser, H. C., Peck, K. Y., Dinh, D., Roberts, L., Chandrasekhar, J., Brennan, A et al., (2022). Role of renin–angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction. *Clinical Research in Cardiology*, 111(7), 776–786. <https://doi.org/10.1007/s00392-021-01985-x>
- Ralapanawa, U., & Sivakanesan, R. (2021). Epidemiology and the Magnitude of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review: *Journal of Epidemiology and Global Health*, 11(2), 169. <https://doi.org/10.2991/jegh.k.201217.001>
- Rear, R., Bell, R. M., & Hausenloy, D. J. (2016). Contrast-induced nephropathy following angiography and cardiac interventions. *Heart*, 102(8), 638–648. <https://doi.org/10.1136/heartjnl-2014-306962>

- Rim, M. Y., Ro, H., Kang, W. C., Kim, A. J., Park, H., Chang, J. H et al., Contrast-Induced Acute Kidney Injury: A Propensity-Matched Study. *American Journal of Kidney Diseases*, 60(4), 576–582. <https://doi.org/10.1053/j.ajkd.2012.04.017>
- Salazar, J. H. (2014). Overview of Urea and Creatinine. *Laboratory Medicine*, 45(1), e19–e20. <https://doi.org/10.1309/LM920SBNZPJRGUT>
- Sastroasmoro, S., & Ismail, S. (2014). *Dasar-dasar Metodologi Penelitian Klinis*. Sagung Seto.
- Selistijo, S. A., Lindarto, D., & Permana, H. (2019). *Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia*. PB PERKENI.
- Singh, A., Museedi, A. S., & Grossman, S. A. (2022). Acute Coronary Syndrome. In *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK459157/>
- Singh, S., Kanwar, A., Sundaragiri, P. R., Cheungpasitporn, W., Truesdell, A. G., Rab, S. T., Singh, M et al., (2021). Acute Kidney Injury in Cardiogenic Shock: An Updated Narrative Review. *Journal of Cardiovascular Development and Disease*, 8(8), 88. <https://doi.org/10.3390/jcdd8080088>
- Smith, J. N., Negrelli, J. M., Manek, M. B., Hawes, E. M., & Viera, A. J. (2015). Diagnosis and Management of Acute Coronary Syndrome: An Evidence-Based Update. *The Journal of the American Board of Family Medicine*, 28(2), 283–293. <https://doi.org/10.3122/jabfm.2015.02.140189>
- Sugiyono. (2011). *Metode Penelitian Kuantitatif, Kualitatif Dan R&D*. ALFABETA.
- Taegtmeyer, H., & Ingwall, J. S. (2013). Creatine—A Dispensable Metabolite? *Circulation Research*, 112(6), 878–880. <https://doi.org/10.1161/CIRCRESAHA.113.300974>
- The Heart Outcomes Prevention Evaluation Study Investigators*. (2000). Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. *New England Journal of Medicine*, 342(3), 145–153. <https://doi.org/10.1056/NEJM200001203420301>
- Theofilis, P., Oikonomou, E., Chasikidis, C., Tsioufis, K., & Tousoulis, D. (2023). Pathophysiology of Acute Coronary Syndromes—Diagnostic and Treatment Considerations. *Life*, 13(7), 1543. <https://doi.org/10.3390/life13071543>
- Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., White et al., (2018). Fourth Universal Definition of Myocardial Infarction (2018). *Circulation*, 138(20). <https://doi.org/10.1161/CIR.0000000000000617>
- Tubaro, M., Vranckx, P., Price, S., Vrints, C., & Bonnefoy, E. (Eds.). (2021). *The ESC Textbook of Intensive and Acute Cardiovascular Care* (3rd ed.). Oxford University Press. <https://doi.org/10.1093/med/9780198849346.001.0001>
- Tylicki, L., Larczynski, W., & Rutkowski, B. (2005). Renal Protective Effects of the Renin-Angiotensin-Aldosterone System Blockade: From Evidence-Based Approach to Perspectives. *Kidney and Blood Pressure Research*, 28(4), 230–242. <https://doi.org/10.1159/000087842>

- Vargas Vargas, R. A., Varela Millán, J. M., & Fajardo Bonilla, E. (2022). Renin-angiotensin system: Basic and clinical aspects—A general perspective. *Endocrinología, Diabetes y Nutrición (English Ed.)*, 69(1), 52–62. <https://doi.org/10.1016/j.endien.2022.01.005>
- Vogt, L., Kocks, M. J. A., Laverman, G. D., & Navis, G. (2004). Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? *Minerva Medica*, 95(5), 395–409.
- Wasilewski, M., Roy, S., Patel, N. G., & Jovin, I. S. (2021). Angiotensin-Converting Enzyme Inhibitors and Contrast-Associated Acute Kidney Injury After Coronary Angiography and Intervention. *American Journal of Cardiovascular Drugs*, 21(5), 487–497. <https://doi.org/10.1007/s40256-020-00455-5>
- Widimsky, P., Crea, F., Binder, R. K., & Lüscher, T. F. (2019). The year in cardiology 2018: Acute coronary syndromes. *European Heart Journal*, 40(3), 271–282. <https://doi.org/10.1093/eurheartj/ehy904>
- Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M et al., (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. *European Heart Journal*, 39(33), 3021–3104. <https://doi.org/10.1093/eurheartj/ehy339>
- Wyss, M., & Kaddurah-Daouk, R. (2000). Creatine and Creatinine Metabolism. *Physiological Reviews*, 80(3), 1107–1213. <https://doi.org/10.1152/physrev.2000.80.3.1107>
- Yuan, D., Chu, J., Qian, J., Lin, H., Zhu, G., Chen, F et al., (2023). New Concepts on the Pathophysiology of Acute Coronary Syndrome. *Reviews in Cardiovascular Medicine*, 24(4), 112. <https://doi.org/10.31083/j.rcm2404112>